Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the united states

Journal of Studies on Alcohol and Drugs

Volumn 74, Issue 2, 2013, Pages 258-265

  Abraham, Amanda J ^a   Knudsen, Hannah K ^b   Rieckmann, Traci ^c   Roman, Paul M ^d  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873925477     PISSN: 19371888     EISSN: 19384114     Source Type: Journal    
DOI: 10.15288/jsad.2013.74.258     Document Type: Article

References (76)

1. Abraham, A. J., Ducharme, L. J., & Roman, P. M. (2009). Counselor attitudes toward pharmacotherapies for alcohol dependence. Journal of Studies on Alcohol and Drugs, 70, 628-635.
2. Abraham, A. J., Knudsen, H. K., & Roman, P. M. (2011). A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: Patterns of sustainability and discontinuation. Journal of Studies on Alcohol and Drugs, 72, 669-677.
3. Abraham, A. J., Knudsen, H. K., Rothrauff, T. C., & Roman, P. M. (2010). The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation. Journal of Substance Abuse Treatment, 38, 275-283.
4. Abraham, A. J., & Roman, P. M. (2010). Early adoption of injectable naltrexone for alcohol-use disorders: Findings in the private-treatment sector. Journal of Studies on Alcohol and Drugs, 71, 460-466.
5. Allison, P. D. (2002). Missing data. Thousand Oaks, CA: Sage.
6. Allison, P. D. (2009). Missing data. In R. E. Millsap & A. Maydeu-Olivares (Eds.), The SAGE handbook of quantitative methods in psychology (pp. 72-89). Thousand Oaks, CA: Sage.
7. Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011). Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Medicine, 12, 657-667.
8. Bouchery, E. E., Harwood, H. J., Sacks, J. J., Simon, C. J., & Brewer, R. D. (2011). Economic costs of excessive alcohol consumption in the U.S., 2006. American Journal of Preventive Medicine, 41, 516-524.
9. Buck, J. A. (2011). The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs, 30, 1402-1410.
10. Cartwright, W. S., & Solano, P. L. (2003). The economics of public health: Financing drug abuse treatment services. Health Policy, 66, 247-260.
11. Center for Substance Abuse Treatment. (2009). Incorporating alcohol phar-macotherapies into medical practice (Treatment Improvement Protocol #49). Rockville, MD: Substance Abuse and Mental Health Services Administration.
12. Chriqui, J. F., Terry-McElrath, Y., McBride, D. C., & Eidson, S. S. (2008). State policies matter: The case of outpatient drug treatment program practices. Journal of Substance Abuse Treatment, 35, 13-21.
13. Coviello, D. M., Cornish, J. W., Lynch, K. G., Boney, T. Y., Clark, C. A., Lee, J. D., OBrien, C. P. (2012). A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Substance Abuse, 33, 48-59.
14. Croft, B., & Parish, S. L. (2012). Care integration in the Patient Protection and Affordable Care Act: Implications for behavioral health. Administration and Policy in Mental Health and Mental Health Services Research. Advance online publication. Retrieved from http://www.springerlink. com/content/8j48330521w01046/fulltext.pdf
15. Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & McLaren, J. (2011). Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. Addiction, 106, 32-51.
16. DiMaggio, P. J., & Powell, W. W. (1991). The new institutionalism in organizational analysis. Chicago, IL: University of Chicago Press.
17. Ducharme, L. J., Knudsen, H. K., & Roman, P. M. (2006). Trends in the adoption of medications for alcohol dependence. Journal of Clinical Pharmacology, 26, Supplement 1, S13-S19.
18. Fuller, B. E., Rieckmann, T., McCarty, D., Smith, K. W., & Levine, H. (2005). Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment, 28, 273-280.
19. Garner, B. R. (2009). Research on the diffusion of evidence-based treatments within substance abuse treatment: A systematic review. Journal of Substance Abuse Treatment, 36, 376-399.
20. Heinrich, C. J., & Fournier, E. (2004). Dimensions of publicness and performance in substance abuse treatment organizations. Journal of Policy Analysis and Management, 23, 49-70.
21. Horgan, C. M., Reif, S., Hodgkin, D., Garnick, D. W., & Merrick, E. L. (2008). Availability of addiction medications in private health plans. Journal of Substance Abuse Treatment, 34, 147-156.
22. Kinlock, T. W., Gordon, M. S., Schwartz, R. P., & Fitzgerald, T. T. (2010). Developing and implementing a new prison-based buprenorphine treatment program. Journal of Offender Rehabilitation, 49, 91-109.
23. Knudsen, H. K., & Abraham, A. J. (2012). Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders. Psychiatric Services, 63, 19-25.
24. Knudsen, H. K., Abraham, A. J., & Oser, C. B. (2011a). Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Evaluation and Program Planning, 34, 375-381.
25. Knudsen, H. K., Abraham, A. J., & Roman, P. M. (2011b). Adoption and implementation of medications in addiction treatment programs. Journal of Addiction Medicine, 5, 21-27.
26. Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2006). Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment, 30, 363-373.
27. Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2007a). The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence, 87, 164-174.
28. Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2007b). Research network involvement and addiction treatment center staff: Counselor attitudes toward buprenorphine. The American Journal on Addictions, 16, 365-371.
29. Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2007c). The use of anti-depressant medications in substance abuse treatment: The public-private distinction, organizational compatibility, and the environment. Journal of Health and Social Behavior, 48, 195-210.
30. Knudsen, H. K., Oser, C. B., Abraham, A. J., & Roman, P. M. (2012). Physicians in the substance abuse treatment workforce: Understanding their employment within publicly funded treatment organizations. Journal of Substance Abuse Treatment, 43, 152-160.
31. Knudsen, H. K., Roman, P. M., Ducharme, L. J., & Johnson, J. A. (2005). Organizational predictors of pharmacological innovation adoption: The case of disulfiram. Journal of Drug Issues, 35, 559-573.
32. Knudsen, H. K., Roman, P. M., & Oser, C. B. (2010). Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations. Journal of Addiction Medicine, 4, 99-107.
33. Koch, A. L., Arfken, C. L., & Schuster, C. R. (2006). Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug and Alcohol Dependence, 83, 274-278.
34. Krupa, C. (2011, June 6). First addiction medicine residencies to begin in July. Retrieved from http://www.ama-assn.org/amednews/2011/06/06/ prsa0606.htm
35. Krupitsky, E., Zvartau, E., & Woody, G. (2010). Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Current Psychiatry Reports, 12, 448-453.
36. Lamb, S., Greenlick, M. R., & McCarty, D. E. (1998). Bridging the gapbetween practice and research: Forging partnerships with community-based drug and alcohol treatment. Washington, D.C.: National Academy Press.
37. Ling, W., Amass, L., Shoptaw, S., Annon, J. J., Hillhouse, M., Babcock, D., Ziedonis, D., & the Buprenorphine Study Protocol Group. (2005). A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction, 100, 1090-1100.
38. Long, J. S. (1997). Regression models for categorical and limited dependent variables. Thousand Oaks, CA: Sage.
39. Long, J. S., & Freese, J. (2006). Regression models for categorical dependent variables using Stata, 2nd edition. College Station, TX: StataCorp.
40. Mark, T. L., Levit, K. R., Vandivort-Warren, R., Buck, J. A., & Coffey, R. M. (2011). Changes in US spending on mental health and substance abuse treatment, 1986-2005, and implications for policy. Health Affairs, 30, 284-292.
41. Mark, T. L., Woody, G. E., Juday, T., & Kleber, H. D. (2001). The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence, 61, 195-206.
42. McCarty, D., Gustafson, D., Capoccia, V. A., & Cotter, F. (2009). Improving care for the treatment of alcohol and drug disorders. Journal of Behavioral Health Services & Research, 36, 52-60.
43. Mechanic, D. (2012). Seizing opportunities under the Affordable Care Act for transforming the mental and behavioral health system. Health Affairs, 31, 376-382.
44. Mee-Lee, D., Gartner, L., Miller, M. M., Shulman, G. R., & Wilford, B. B. (1996). Patient placement criteria for the treatment of substance-related disorders (2nd ed.). Chevy Chase, MD: American Society of Addiction Medicine.
45. Mental Health Parity and Addiction Equity Act of 2008. H.R. 6983, 110th Cong. (2008). Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008.
46. Miller, N. S., Sheppard, L. M., Colenda, C. C., & Magen, J. (2001). Why physicians are unprepared to treat patients who have alcohol-and drug-related disorders. Academic Medicine, 76, 410-418.
47. Mokdad, A. H., Marks, J. S., Stroup, D. F., & Gerberding, J. L. (2004). Actual causes of death in the United States, 2000. Journal of the American Medical Association, 291, 1238-1245.
48. Mokdad, A. H., Marks, J. S., Stroup, D. F., & Gerberding, J. L. (2005). Correction: Actual causes of death in the United States, 2000. Journal of the American Medical Association, 293, 293-294.
49. National Drug Intelligence Center. (2011). The economic impact of illicit drug use on American society. Washington, DC: U.S. Department of Justice.
50. National Institute on Alcohol Abuse and Alcoholism. (2007). Helping patients who drink too much: A clinician's guide (NIH Publication No. 07-3769). Bethesda, MD: National Institutes of Health.
51. National Institute on Drug Abuse. (2009). Principles of drug addiction treatment: A research-based guide (NIH Publication No. 09-4180). Rockville, MD: National Institutes of Health.
52. Office of National Drug Control Policy. (2010). National drug control strategy. Washington, DC: Author.
53. Office of National Drug Control Policy. (2011). National drug control strategy. Washington, DC: Author.
54. O'Malley, S. S., Garbutt, J. C., Gastfriend, D. R., Dong, Q., & Kranzler, H. R. (2007). Effi cacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. Journal of Clinical Psycho-pharmacology, 27, 507-512.
55. Oser, C. B., & Roman, P. M. (2007). Organizational-level predictors of adoption across time: Naltrexone in private substance-use disorders treatment centers. Journal of Studies on Alcohol and Drugs, 68, 852-861.
56. Oser, C. B., & Roman, P. M. (2008). A categorical typology of naltrexone-adopting private substance abuse treatment centers. Journal of Substance Abuse Treatment, 34, 433-442.
57. Patient Protection and Affordable Care Act of 2010. (2010). Public Law No. 111-148, 124 Stat. 119, 42 U.S.C. § 18001.
58. Pfeffer, J. S., & Salancik, G.R. (2003). The external control of organizations: A resource dependence perspective. Stanford, CA: Stanford University Press.
59. Polydorou, S., Gunderson, E. W., & Levin, F. R. (2008). Training physicians to treat substance use disorders. Current Psychiatry Reports, 10, 399-404.
60. Rodgers, J. H., & Barnett, P. G. (2000). Two separate tracks? A national multivariate analysis of differences between public and private substance abuse treatment programs. American Journal of Drug and Alcohol Abuse, 26, 429-442.
61. Rogers, E. M. (2003). Diffusion of innovations. New York, NY: Free Press.
62. Roman, P. M., Abraham, A. J., & Knudsen, H. K. (2011). Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. Addictive Behaviors, 36, 584-589.
63. Roman, P. M., & Johnson, J. A. (2002). Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment, 22, 211-218.
64. Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2011). Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews, Issue 9, Article No. CD004332.
65. Rösner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., & Soyka, M. (2010). Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews, Issue 12, Article No. CD001867.
66. Royston, P. (2005a). Multiple imputation of missing values: Update. The Stata Journal, 5(2), 188-201. Retrieved from http://www.stata-journal. com/article.html?article=st0067_1
67. Royston, P. (2005b). Multiple imputation of missing values: Update of ice. The Stata Journal, 5(4), 527-536. Retrieved from http://www.stata-journal.com/article.html?article=st0067_2
68. StataCorp. (2011). Stata Statistical Software: Version 12. College Station, TX: StataCorp.
69. Stewart, M. T., & Horgan, C. M. (2011). Health services and financing of treatment. Alcohol Research & Health, 33, 389-394.
70. Substance Abuse and Mental Health Services Administration. (2009a). National Survey of Substance Abuse Treatment Services: 2009. Bethesda, MD: Author.
71. Substance Abuse and Mental Health Services Administration. (2009b). Treatment Episode Data Set (TEDS). Highlights-2007. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Author.
72. Substance Abuse and Mental Health Services Administration. (2011). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings (NSDUH Series H-41, HHS Publication No. SMA 11-4658). Rockville, MD: Author.
73. Thomas, C. P., Reif, S., Haq, S., Wallack, S. S., Hoyt, A., & Ritter, G. A. (2008). Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services, 59, 909-916.
74. Thomas, C. P., Wallack, S. S., Lee, S., McCarty, D., & Swift, R. (2003). Research to practice: adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 24, 1-11.
75. Wheeler, J. R., & Nahra, T. A. (2000). Private and public ownership in outpatient substance abuse treatment: Do we have a two-tiered system? Administration and Policy in Mental Health, 27, 197-209.
76. White, W. (1998). Slaying the dragon: The history of addiction treatment and recovery in America. Bloomington, IL: Chestnut Health Systems.